<DOC>
	<DOCNO>NCT00002433</DOCNO>
	<brief_summary>To determine safety tolerance administer aerosolize recombinant interferon gamma ( IFN-gamma ) 4 week patient AIDS . To examine activation alveolar macrophage aerosolize IFN-gamma administration . To determine subcutaneous ( SC ) injection IFN-gamma activate alveolar macrophage AIDS patient .</brief_summary>
	<brief_title>The Effects r-metHuIFN-Gamma Lungs Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion Criteria Patients must : Diagnosis AIDS one opportunistic infection . Kaposi 's sarcoma prior history opportunistic infection . Stable dose zidovudine ( AZT ) therapy . Preserved pulmonary , renal hepatic function . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Presence active infection . Active opportunistic infection . Cardiac disease . Central nervous system disorder . History seizure . Irreversible airway disease . Patients follow exclude : Coexisting condition symptom list Patient Exclusion Coexisting Conditions . Prior Medication : Excluded within 4 week study entry : Immunosuppressive therapy . Cytotoxic therapy . Excluded : Interferon gamma therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Pulmonary Alveoli</keyword>
	<keyword>Macrophage Activation</keyword>
	<keyword>Interferon-gamma , Recombinant</keyword>
	<keyword>Injections , Subcutaneous</keyword>
	<keyword>Aerosols</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>